^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET fusion

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) (NCT03175224)
    Phase 2
    Apollomics Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    09/27/2017
    Primary completion :
    03/30/2026
    Completion :
    11/30/2026
    HGF • PTPRZ1
    |
    EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion
    |
    vebreltinib (APL-101) • CBT101
    Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) (NCT03993873)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/20/2023
    Initiation :
    09/21/2019
    Primary completion :
    03/02/2025
    Completion :
    03/02/2025
    MET
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET fusion
    |
    elzovantinib (TPX-0022)
    Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer (NCT03088930)
    Phase 2
    University of Colorado, Denver
    Completed
    Last update posted :
    02/11/2022
    Initiation :
    12/13/2017
    Primary completion :
    01/13/2021
    Completion :
    01/13/2021
    ALK • MET • ROS1
    |
    ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • MET fusion
    |
    Xalkori (crizotinib)